Can COVID-19 Cause Fibromyalgia? A Look at the Evidence

A growing body of research suggests that COVID-19 can trigger fibromyalgia, or at the very least a condition that looks and feels almost identical to it. In controlled studies, people who recovered from COVID-19 were roughly three times more likely to meet formal fibromyalgia diagnostic criteria than people who had not been infected. The connection isn’t surprising once you look under the hood: the virus appears to set off a cascade of immune and nervous system changes that closely mirror the processes researchers already associate with fibromyalgia. But the story is more nuanced than a simple cause-and-effect, and understanding those nuances matters for anyone stuck in the limbo of unexplained post-COVID pain.

How Often Fibromyalgia Appears After COVID-19

The numbers vary depending on how and when researchers look, but they consistently point in the same direction. A web-based survey of people who had recovered from COVID-19 found that about 31% met the classification criteria for fibromyalgia roughly six months after their initial diagnosis.¹ That figure is strikingly high, though it comes with the caveat that web surveys tend to attract people who are symptomatic, which inflates prevalence estimates.

A more tightly controlled case-control study paints a less dramatic but still concerning picture. Using formal diagnostic criteria, researchers found fibromyalgia in about 14% of post-COVID patients compared with 5% of matched controls, translating to roughly three-to-one odds of developing fibromyalgia after infection.² Whether those individuals would have eventually developed fibromyalgia without the infection is impossible to say with certainty, but the gap between the two groups is hard to dismiss as coincidence. Multiple review papers have independently concluded that fibromyalgia-related symptoms appear in a meaningful subset of people following COVID-19.³

One interesting wrinkle: severity of the initial infection doesn’t seem to predict who develops fibromyalgia afterward. A study tracking hospitalized patients found that neither the severity of their acute illness nor the length of their hospital stay was significantly associated with post-COVID fibromyalgia.⁴ You didn’t need to have been on a ventilator. Mild cases could apparently trip the same wire.

When Long COVID and Fibromyalgia Blur Together

One of the biggest practical challenges for patients and clinicians alike is that long COVID and fibromyalgia share an almost absurd amount of symptom overlap. Widespread pain, crushing fatigue, cognitive fog, sleep problems, mood disturbances, and gastrointestinal complaints are hallmarks of both conditions. Researchers have pointed out that once you strip away patients with clear organ damage from the long COVID population, what remains looks remarkably like fibromyalgia or chronic fatigue syndrome.⁵

That doesn’t mean the two conditions are identical. A survey study directly comparing them found that people with post-COVID symptoms generally reported less severe pain than those with established fibromyalgia and less severe fatigue than those with chronic fatigue syndrome. But they reported equally poor physical function and equal or even greater cognitive limitations.⁶ So the post-COVID version may present as a slightly different flavor of the same syndrome: less raw pain intensity, but potentially just as debilitating in terms of what you can actually do day to day. About 8% of the post-COVID group in that study scored high enough on a fibromyalgia severity measure to cross the formal diagnostic threshold, while the rest fell below it but were still clearly not well.

This overlap creates a diagnostic gray zone. If you developed widespread pain and fatigue after a COVID infection, are you dealing with “long COVID,” newly triggered fibromyalgia, or both? Clinically, the distinction may not change treatment much, since both conditions are managed with similar strategies. But for research purposes, and for patients trying to understand what’s happening to them, untangling the two remains a live and unresolved problem.

What the Virus Does to the Nervous System

The leading explanation for why COVID-19 might trigger fibromyalgia centers on something called central sensitization, a state in which the nervous system becomes stuck in a kind of high-alert mode. Pain signals get amplified, sensory thresholds drop, and stimuli that shouldn’t hurt suddenly do. This is already considered a core feature of fibromyalgia itself. Researchers have argued that once you exclude long COVID patients with identifiable organ damage, the remaining syndrome fits best as a model of central sensitization.⁷

Pain after COVID-19 can take several forms. Some of it is straightforward tissue damage or nerve injury from the infection itself. But the more puzzling and persistent type appears to be nociplastic pain, meaning pain that arises from altered processing in the nervous system rather than from ongoing damage or nerve lesions. Evidence suggests that this nociplastic mechanism is probably the primary driver of persistent post-COVID pain, and it tends to come bundled with poor sleep, fatigue, and cognitive-emotional disturbances.⁸ That bundle, of course, is essentially a description of fibromyalgia.

The similarities between the two conditions extend beyond symptoms down to their underlying biology. A review paper laid out the parallel pathways, noting that the SARS-CoV-2 virus affects both the central and peripheral nervous systems, producing musculoskeletal, neurological, and psychological disturbances that can persist for at least a year after recovery.⁹ The overlap between these mechanisms and those of established fibromyalgia led the authors to speculate that the virus could serve as either a trigger for new fibromyalgia or an amplifier of pre-existing subclinical symptoms.

Inflammation That Doesn’t Quit

One concrete way COVID-19 may flip the switch toward fibromyalgia is through runaway inflammation in the nervous system. The immune response to the virus produces a flood of inflammatory signaling molecules. While that’s a normal part of fighting off infection, the problem arises when those molecules stick around after the virus is gone or when they reach the spinal cord and brain in quantities that rewire pain processing.

A review of the cytokine pathways involved in long COVID found that elevated levels of these inflammatory signals, both in the body and in the central nervous system, can produce fatigue, post-exertional malaise, brain fog, joint pain, nerve tingling, and gut problems.¹⁰ These are, again, the defining features of fibromyalgia. Separately, researchers examining how the virus interacts with pain-sensing nerve fibers concluded that the intense immune storm triggered by COVID-19 could lead to chronic pain.¹¹

Animal research has added a finer level of detail. In mouse studies, a protein from the SARS-CoV-2 virus’s outer shell triggered inflammation via immune cells in both the skin and the spinal cord, activating a well-known inflammatory signaling pathway. The protein ramped up production of several pro-inflammatory molecules and caused changes in pain-related nerve signaling in both male and female mice.¹² This kind of work suggests that viral proteins themselves, even without active viral replication, can kick the nervous system into a pain-sensitized state.

The Autoimmune Angle

A more provocative line of research asks whether COVID-19 might trigger fibromyalgia through autoimmunity, where the immune system begins attacking the body’s own tissues. This idea gained traction when studies found that transferring antibodies from fibromyalgia patients into healthy mice could reproduce pain-like behaviors in the animals, suggesting that something in the patients’ blood was directly causing pain.¹³

Researchers have since looked at whether post-COVID patients develop similar self-targeting antibodies. A study examining antibodies against satellite glial cells, supportive cells in nerve clusters, found that post-COVID patients did show high levels of these antibodies. Interestingly, though, the staining pattern in post-COVID patients was very high and actually indistinguishable from recovered controls, while differing from the pattern seen in fibromyalgia patients.¹⁴ That means the autoimmune processes at work in the two conditions may overlap in some ways but diverge in others. The field is still early here, and the science of antibody-mediated pain remains something researchers openly say will require substantial effort to unravel.

Small Fiber Damage and Muscle Changes

Beyond central nervous system changes, COVID-19 also appears capable of damaging the peripheral nerves and muscles in ways relevant to fibromyalgia. Using a specialized imaging technique that examines the tiny nerve fibers in the cornea of the eye, a proxy for small nerve fiber health throughout the body, researchers found that COVID-19 patients showed significant alterations compared to healthy controls. Their nerve fibers were fewer, thinner, and showed more structural abnormalities.¹⁵ Small fiber neuropathy has been proposed as a contributing factor in at least some fibromyalgia patients, so this overlap offers another potential connection point.

At the muscle level, biopsy studies of severely ill COVID-19 patients have revealed damage to the tiny blood vessels running through muscle tissue. The most consistent finding was injury to the cells lining these micro-vessels, with signs of repeated damage and repair that could impair blood flow to muscles long after the acute infection resolves.¹⁶ While this particular study focused on severe cases, the finding raises questions about whether subtler versions of the same vascular damage might contribute to the widespread muscle pain that characterizes both long COVID and fibromyalgia.

Who Is Most Vulnerable

Not everyone who gets COVID-19 develops fibromyalgia, and researchers have been working to identify who’s at greatest risk. The clearest risk factor is sex: women are significantly more likely than men to develop post-COVID fibromyalgia, with one study reporting roughly three-and-a-half-fold higher odds for women.⁴ This mirrors the known sex distribution of fibromyalgia in the general population, where women are diagnosed far more often than men.

Psychological and personality factors also play a role. The same study found that people with higher scores on a measure of self-transcendence, a personality trait related to spiritual self-awareness and feelings of connectedness, and lower scores on a measure of sense of coherence, which reflects the ability to view life as manageable and meaningful, were significantly more likely to develop post-COVID fibromyalgia. These aren’t necessarily causal: people who perceive the world as less predictable and manageable may be more vulnerable to conditions influenced by central nervous system sensitization, or these personality profiles may simply be markers for underlying neurobiological predispositions.

A separate longitudinal study of hospitalized COVID-19 patients identified another set of predictors. Higher anxiety and depression severity early in recovery, worse insomnia, and reduced grip strength all independently increased the risk of developing chronic pain and fibromyalgia-like symptoms down the line.¹⁷ The authors emphasized that several of these, especially psychological distress, sleep disruption, and muscle weakness, are modifiable, meaning that aggressively treating them early in recovery might reduce the chances of chronic pain taking hold.

The People Who Already Had Fibromyalgia

A separate question from whether COVID-19 can trigger new fibromyalgia is what happens when someone who already has fibromyalgia catches the virus. One study compared the rate of lingering post-COVID symptoms between fibromyalgia patients and patients with other rheumatic diseases. About 80% of the fibromyalgia group reported persistent symptoms after their COVID infection, compared to 66% of the other rheumatic disease group, though the difference didn’t reach statistical significance.¹⁸ The trend, even if not conclusive, suggests that people with pre-existing fibromyalgia may be somewhat more prone to prolonged COVID symptoms. Anecdotally, many fibromyalgia patients report flare-ups of their condition following any significant infection, and COVID-19 appears to be no exception.

Does Vaccination Help

Given that COVID-19 may set off the chain of events leading to fibromyalgia, the natural question is whether vaccination can prevent that chain from starting. A large cohort study found that COVID-19 survivors who had been vaccinated had a roughly 16% lower risk of developing new fibromyalgia compared to unvaccinated survivors.¹⁹ The reduction was statistically significant but moderate, which makes sense: vaccines reduce the severity of infection and the intensity of the immune response, but they don’t eliminate it entirely. Less immune chaos during the acute phase presumably means less collateral damage to the nervous system afterward.

This finding carries a practical implication. Even people who have already had COVID-19 may benefit from staying up to date on vaccination, not just to prevent reinfection but potentially to reduce the risk of developing chronic pain syndromes with subsequent exposures. The evidence on this point is still accumulating, but the direction of the data is encouraging.

Managing Post-COVID Fibromyalgia

For people who have already developed fibromyalgia symptoms after COVID-19, the treatment landscape currently looks similar to what’s offered for fibromyalgia from any other cause. There is no specific cure for either condition. Current approaches are symptom-targeted and typically combine medications with non-drug strategies: adequate hydration, compression garments for circulation issues, gradually progressive physical activity, meditation, biofeedback, cognitive rehabilitation for brain fog, and treatment of co-occurring mood disorders.²⁰

The emphasis on gradual physical activity deserves special mention. Many post-COVID patients experience worsening symptoms after exertion, which makes it tempting to avoid exercise altogether. But prolonged inactivity feeds into the cycle of muscle deconditioning and central sensitization that maintains chronic pain. Finding the right balance, doing enough to prevent deconditioning without triggering a crash, is one of the trickiest parts of recovery and usually requires guidance from a clinician experienced with these conditions.

The risk factor research also suggests an early-intervention window. Because anxiety, poor sleep, and muscle weakness during the acute recovery period predict later development of fibromyalgia symptoms, there’s a reasonable argument for screening recovering COVID-19 patients for these issues and treating them aggressively. Whether formal intervention trials will bear that logic out remains to be seen, but the biological rationale is solid.

What Researchers Still Can’t Say for Sure

The evidence clearly points to a connection between COVID-19 and fibromyalgia, but researchers are the first to acknowledge open questions. Most of the existing studies are observational, meaning they show an association without definitively proving causation. It’s possible that the stress, isolation, sleep disruption, and physical deconditioning that came with the pandemic itself, rather than the virus specifically, could be contributing to the rise in fibromyalgia diagnoses. The personality and psychological factors identified as risk factors lend some weight to this alternative explanation, though they don’t rule out a direct viral trigger.

It’s also unclear how durable post-COVID fibromyalgia is over time. Many long COVID symptoms gradually improve over one to two years, and some people who meet fibromyalgia criteria at six months may no longer meet them at two or three years. Long-term follow-up studies are still underway. Conversely, fibromyalgia triggered by other infections or injuries often becomes a chronic, lifelong condition, and there’s no obvious reason to expect the post-COVID version to behave differently.

Perhaps the most fundamental unresolved question is whether post-COVID fibromyalgia is truly “new” fibromyalgia or whether the virus is unmasking a pre-existing vulnerability. Some people may have been on the edge of developing fibromyalgia for years, with the immune upheaval of COVID-19 simply pushing them over the threshold. The immune, neurological, and even psychological characteristics that predispose someone to post-COVID fibromyalgia overlap heavily with the known risk profile for fibromyalgia in general, which suggests that the virus may be accelerating a process rather than creating one from scratch in many cases. For the person living with the pain, of course, the distinction is academic. What matters is that the symptoms are real, they have plausible biological underpinnings, and the same management strategies apply regardless of the initial trigger.